News

Notice of Change in President & CEO

As of May 26th, Teruo Susumu has resigned from his position as President and CEO at aceRNA Technologies. Fumihiro Sugawa will serve as the new President and CEO. We will continue to develop “smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner.

We and Nitto Denko entered into an agreement to jointly develop Switch mRNA Therapy

Related link: Press release

Close of Series B funding

aceRNA Technologies has raised funds from Nitto Denko and Mitsubishi UFJ Capital. aceRNA will use this capital to develop “smart gene therapy” (mRNA-based and virus-base) that enables
control of therapeutic transgene expression in cell-type and -state specific manner.

We have been selected for the Startup City Acceleration Program promoted by the Japan External Trade Organization (JETRO).

Related link (in Japanese):https://www.jetro.go.jp/news/releases/2021/af727f3ff68fbc5e.html

We received Senju Pharmaceutical Award at Medtech Grand Prix KOBE2021 organized by Leave a Nest Co., Ltd.

Related link (in Japanese):https://techplanter.com/2021/10/11/medtechkobe2021/

We won 2nd Prize in Boehringer Ingelheim Innovation Prize 2021.

Related link (in Japanese):https://www.boehringer-ingelheim.jp/press-release/20211013_02

We have entered into a joint research agreement withJCR Pharmaceuticals.

We are pleased to announce that we have signed a joint research agreement with JCR Pharmaceuticals for the purpose of modifying cell functions by controlling gene expression using our RNA Switch® technology.

Related link (in Japanese):Press release

Launch of drug resistance gene mRNA products.

In addition to the puromycin resistance gene mRNA already on the market, we have added blastcidin and hygromycin resistance gene mRNA to our product lineup. In addition to our RNA switch, by co-transferring with Cas9 mRNA or siRNA of other companies, cells with untransfected nucleic acid can be removed by drug treatment.

Related link (in Japanese):https://bio.nikkeibp.co.jp/atcl/news/p1/21/04/02/08026

Close of Series A funding

aceRNA Technologies has raised funds from Kyoto University Innovation Capital, SMBC Venture Capital, and several individual investors.

aceRNA will use this capital to explore regenerative medicine and drug discovery targets using our technology.

Related link (in Japanese):http://www.kyoto-unicap.co.jp/unicap/wp-content/uploads/aceRNA-technologies_Press-release_20191031.pdf

Launch of cell sorting reagents utilizing RNA switch technology

We are pleased to announce the commercialization and launch of a cell sorting reagent that utilizes RNA Switch™ technology. This product utilizes the RNA Switch™ technology invented by Professor Hirohide Saito and his colleagues at the Kyoto University iPS Cell Research Institute, and is a reagent that can identify or sort only specific cell types. The RNA switch for sorting using suicide genes is expected to make a significant contribution to the improvement of productivity in the research field, as it allows for quick and easy research without the use of special machinery by simply introducing it into cells.

Close of seed round funding.

aceRNA Technologies, which is based on the RNA switch technology invented by Professor Hirohide Saitoh of the Kyoto University iPS Cell Research Institute, has raised capital from Kyoto University Innovation Capital. We are pleased to announce that we will use the funds raised to promote research and development for the sale of RNA switch research reagents, and to further grow our business.